Inhalte werden geladen...
From the initial idea to the finished therapy: We bring your medical innovation to life
Lonza is a leading global CDMO offering integrated development and manufacturing services for the pharma, biotech, and healthcare industries.
Independent B2B performance index (0–100 points) for service providers. It is calculated mathematically and without subjective influence from four verified pillars: stability and experience, aggregated feedback from publicly available online sources, documented quality and industry certifications, and transparency about services and terms. Comparable with other service providers.
BenchTrust Index weighting: Stability & experience 20 points · Customer reviews 30 points · Quality & certification 25 points · Transparency about services & terms 25 points. Without reviews a neutral average is used; a few reviews move it only slightly
Review data basis: The evaluated platforms contain no reviews for this provider.
Headquarters
Muenchensteinerstrasse 38, 4052 Basel, Switzerland
Employees
19000
Founded
1897
Management
Matthew Moorcroft
Lonza is a leading global Contract Development and Manufacturing Organization (CDMO) headquartered in Basel, Switzerland. Since its founding in 1897, the company has grown into one of the largest Western partners for the pharma, biotech, and healthcare industries. With approximately 19,000 employees worldwide, Lonza helps customers translate therapeutic innovations into life-saving treatments. The service portfolio spans the entire product lifecycle: from early-phase discovery support to custom manufacturing of active pharmaceutical ingredients (APIs) and innovative dosage forms. A particular focus is placed on biologics, small molecules, cell and gene therapies, and capsule solutions for the pharma and nutrition industries. In addition, Lonza offers specialized drug product services, which include formulation, analytical development, and sterile filling in state-of-the-art laboratories. As a global industry leader, Lonza adheres to the highest quality and safety standards. Its manufacturing facilities operate strictly under GMP (Good Manufacturing Practice) guidelines and are certified according to ISO 9001:2015 and HACCP. By combining advanced science, lean manufacturing processes, and global scalability, Lonza enables the rapid and reliable market launch of complex therapies.
Ask about scope of services, experience or collaboration – answers in seconds.
Answers are based on the website and documents of Lonza.
Lonza recently presented strategic initiatives to strengthen its global market position in biopharmaceuticals and contract manufacturing. Through targeted investments to expand production capacities in Europe and the US, the company is responding to the growing demand for complex biologics. Furthermore, innovative drug delivery platforms and new strategic partnerships reinforce its service portfolio for global pharma and biotech customers.
Latest updates